Skip to main content
SpringerLink
Log in

Immunology of Transplantation

  • Chapter
Surgery

  • 306 Accesses

Abstract

Tissues transferred between genetically nonidentical individuals are destroyed through a process known broadly as rejection. It has been apparent throughout most of medical history that these tissues could provide relief from disease if they were not rejected. Thus, the field of transplantation has grown in tandem with the understanding of the biology of rejection and, to the extent that rejection is an immune-mediated process, of the immune system in general. This close relationship between immunological science and clinical transplantation has fueled remarkable progress in our understanding of immune function and of the fundamental nature of our existence as individuals. The components of the immune system that have been defined in this context are now widely recognized not only for their importance in graft rejection but also for their roles in infection control, shock, tumor growth, autoimmune disease, and the systemic response to trauma. As such, the understanding of immunology that has been born of the study of transplantation has become key to the thorough understanding of the biology of modern medicine and surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carrel A. La technique operatoire des anastomoses vasculaires et la transplantation des visceres. Lyon Med 1902;98:859.

    Google Scholar 

  2. Carrel A. Results of the transplantation of blood vessels, organs and limbs. JAMA 1908;51:1662.

    Google Scholar 

  3. Converse JM, Casson PR. The historical background of transplantation. In: Rapaport F, Dausset J, eds. Human Transplantation. New York: Grune and Stratton; 1968.

    Google Scholar 

  4. Terasaki PI, ed. History of Transplantation: Thirty-Five Recollections. Los Angeles: UCLA Tissue Typing Laboratory; 1991.

    Google Scholar 

  5. Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits. J Anat 1944;78:176–199.

    PubMed  CAS  Google Scholar 

  6. Medawar PB. A second study of the behaviour and fate of skin homografts in rabbits. J Anat 1945;79:157–176.

    PubMed  CAS  Google Scholar 

  7. Medawar PB. Immunity to homologous graft skin, I: the suppression of cell division in grafts transplanted to immunized animals. Br J Exp Pathol 1946;27:9.

    Google Scholar 

  8. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400–401.

    Article  PubMed  CAS  Google Scholar 

  9. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603–606.

    Article  PubMed  CAS  Google Scholar 

  10. Mitchison NA. Passive transfer of transplantation immunity. Proc R Soc Lond B Biol Sci 1954;142:72.

    Article  PubMed  CAS  Google Scholar 

  11. Gorer PA. The antigenic basis of tumour transplantation. J Pathol Bacteriol 1938;47:231–252.

    Article  Google Scholar 

  12. Gorer PA, Lyman S, Snell GD. Studies on the genetic and antigenic basis of tumour transplantation: linkage between a histocompatibility gene and “fused” in mice. Proc Soc Lond B Biol Sci 1948;135:499.

    Article  Google Scholar 

  13. Snell GD. Methods for the study of histocompatibility genes. J Genet 1948–1949;49:87–108.

    Article  PubMed  CAS  Google Scholar 

  14. Amos DB, Gorer PA, Mikulska ZB. The antigenic structure and genetic behavior of a transplanted leukosis. Br J Cancer 1955;9:209.

    PubMed  CAS  Google Scholar 

  15. Dausset J, Nenna A, Présence d’une leuco-agglutinine dans le sérum d’un cas d’agranulocytose chronique [Presence of leukoagglutinin in the serum of a case of chronic agranulocytosis]. Compt Rendus Soc Biol (Paris) 1952;146:1539.

    CAS  Google Scholar 

  16. Dausset J. Iso-leuco-anticorps. Acta Haematol 1958;20:156–166.

    Article  PubMed  CAS  Google Scholar 

  17. Bach F, Hirschhorn K. Lymphocyte interaction: a potential histocompatibility test in vitro. Science 1964;143:813–814.

    Article  PubMed  CAS  Google Scholar 

  18. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998–1000.

    Article  PubMed  CAS  Google Scholar 

  19. Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506–511.

    Article  PubMed  CAS  Google Scholar 

  20. Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigen. Nature 1987;329:512–518.

    Article  PubMed  CAS  Google Scholar 

  21. Brown JH, Jardetzky T, Saper MA, et al. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988;332:845–850.

    Article  PubMed  CAS  Google Scholar 

  22. Brown JH, Jardetzky T, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33–39.

    Article  PubMed  CAS  Google Scholar 

  23. Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A 1976;73:3628–3632.

    Article  PubMed  CAS  Google Scholar 

  24. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701–702.

    Article  PubMed  CAS  Google Scholar 

  25. Doherty PC, Zinkernagel RM. T cell-mediated immunopathology in viral infections. Transplant Rev 1974;19:89–120.

    PubMed  CAS  Google Scholar 

  26. Bretscher P, Cohn M. A theory of self-non-self discrimination. Science 1970;169:1042–1049.

    Article  PubMed  CAS  Google Scholar 

  27. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27–42.

    Article  PubMed  CAS  Google Scholar 

  28. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321–331.

    Article  PubMed  CAS  Google Scholar 

  29. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996;271:1723–1726.

    Article  PubMed  CAS  Google Scholar 

  30. Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. Surg Forum 1955;6:432.

    Google Scholar 

  31. Hitchings GH, Elion GB, Falco EA, et al. Antagonists of nucleic acid derivatives, I: the Lactobacillus casei model. J Biol Chem 1950;183:1.

    CAS  Google Scholar 

  32. Hitchings GH, Elion GB. Chemical suppression of the immune response. Pharmacol Rev 1963;15:365.

    PubMed  CAS  Google Scholar 

  33. Calne RY, Murray JE. Inhibition of rejection of renal homografts in dogs by Burroughs-Wellcome 57–322. Surg Forum 1961;12:118–120.

    PubMed  CAS  Google Scholar 

  34. Borel JF, Feurer C, Gubler HU. Biological effects of cyclosporine A: a new antilymphatic agent. Actions Agents 1976;6:468–475.

    Article  CAS  Google Scholar 

  35. Borel JF. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 1976;31:631–641.

    PubMed  CAS  Google Scholar 

  36. Calne RY, White DJ, Rolles K, et al. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1978;1:1183–1185.

    Article  PubMed  CAS  Google Scholar 

  37. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323–1387.

    Article  PubMed  CAS  Google Scholar 

  38. Dempsey PW, Allison MED, Akkaraju S, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348–350.

    Article  PubMed  CAS  Google Scholar 

  39. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50–53.

    Article  PubMed  CAS  Google Scholar 

  40. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431–1433.

    Article  PubMed  CAS  Google Scholar 

  41. Baldwon WM, Pruitt SK, Brauer RB, et al. Complement in organ transplantation. Transplantation 1995;59:797–808.

    Google Scholar 

  42. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245–3287.

    PubMed  CAS  Google Scholar 

  43. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004;4:499–511.

    Article  PubMed  CAS  Google Scholar 

  44. Koo, DDH, Roberts, ISD, et al. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004;78:398–403.

    Article  PubMed  Google Scholar 

  45. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996;272:54–60.

    Article  PubMed  CAS  Google Scholar 

  46. Fearon DT. Seeking wisdom in innate immunity. Nature 1997;388:323–24.

    Article  PubMed  CAS  Google Scholar 

  47. Davis MM, Bjorkman PJ. T cell antigen receptor genes and T cell recognition. Nature 1988;334:395–402.

    Article  PubMed  CAS  Google Scholar 

  48. Cooper MD. B lymphocytes: normal development and function. N Engl J Med 1987;317:1452–1457.

    PubMed  CAS  Google Scholar 

  49. Gill JI, Gulley ML. Immunoglobulin and T cell receptor gene rearrangement. Hematol Oncol Clin North Am 1994;8:751–770.

    PubMed  CAS  Google Scholar 

  50. Kirk AD, Ibrahim S, Dawson DV, et al. Characterization of T cells expressing the γ/δ antigen receptor in human renal allografts. Hum Immunol 1993;36:11–19.

    Article  PubMed  CAS  Google Scholar 

  51. Kappler JW, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273–280.

    Article  PubMed  CAS  Google Scholar 

  52. Bevan MJ. In thymic selection, peptide diversity gives and takes away. Immunity 1997;7:175–178.

    Article  PubMed  CAS  Google Scholar 

  53. Fowlkes BJ, Ramsdell F. T cell tolerance. Curr Opin Immunol 1993;5:873–879.

    Article  PubMed  CAS  Google Scholar 

  54. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233–243.

    Article  PubMed  CAS  Google Scholar 

  55. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189–1192.

    Article  PubMed  CAS  Google Scholar 

  56. Wilson LA, Garcia KC. T cell receptor structure and TCR complexes. Curr Opin Struct Biol 1997;7:839–848.

    Article  PubMed  CAS  Google Scholar 

  57. Rothenberg EV. How T cells count. Science 1996;273:78–79.

    Article  PubMed  CAS  Google Scholar 

  58. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104–106.

    Article  PubMed  CAS  Google Scholar 

  59. Kumagai N, Benedict SH, Mills GB, et al. Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes. J Immunol 1987;139:1393–1399.

    PubMed  CAS  Google Scholar 

  60. Saizawa K, Rojo J, Janeway CA Jr. Evidence for a physical association of CD4 and the CD3: alpha:beta T cell receptor. Nature 1987;328:260–263.

    Article  PubMed  CAS  Google Scholar 

  61. Leahy DJ, Axel R, Hendrickson WA. Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 Å resolution. Cell 1992;68:1145–1162.

    Article  PubMed  CAS  Google Scholar 

  62. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76:287–299.

    Article  PubMed  CAS  Google Scholar 

  63. Monaco JJ. Structure and function of genes in the MHC class II region. Curr Opin Immunol 1993;5:17–20.

    Article  PubMed  CAS  Google Scholar 

  64. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474–478.

    Article  PubMed  CAS  Google Scholar 

  65. Lanzavecchia A. License to kill. Nature 1998;393:413–414.

    Article  PubMed  CAS  Google Scholar 

  66. Plas DR. Johnson R, Pingel JT, et al. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 1996;272:1173–1176.

    Article  PubMed  CAS  Google Scholar 

  67. Marengere LEM, Waterhouse P, Duncan GS, et al. Regulation of T cell receptor signaling by tyrosine phosphatase SYP associated with CTLA-4. Science 1996;272:1170–1173.

    Article  PubMed  CAS  Google Scholar 

  68. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989;243:355–361.

    Article  PubMed  CAS  Google Scholar 

  69. Ullman KS, Northrop JP, Verweij CJ, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990;8:421–452.

    Article  PubMed  CAS  Google Scholar 

  70. Siegel JN, June CH. Signal transduction in T cell activation and tolerance. In: Gupta S, Griscelli C, eds. New Concepts in Immunodeficiency Diseases. New York: Wiley; 1993;85–129.

    Google Scholar 

  71. Karthryn Wood and Shimon Sakaguchi. Regulatory T cells in transplant tolerance. Nat Rev Immunol 2003;3:199–210.

    Article  CAS  Google Scholar 

  72. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135–142.

    Article  PubMed  CAS  Google Scholar 

  73. Baecher-Allan at al. CD4+CD25+ highly regulatory cells in human peripheral blood. J Immunol 2001;167:1245–1253.

    PubMed  CAS  Google Scholar 

  74. Berke G. The CTL’s kiss of death. Cell 1995;81:9–12.

    Article  PubMed  CAS  Google Scholar 

  75. Zouali M. B cell superantigens: implications for selection of the human antibody repertoire. Immunol Today 1995;16:399–405.

    Article  PubMed  CAS  Google Scholar 

  76. Jung S, Rajewsky K, Radbruch A. Shutdown of class switch recombination by deletion of a switch region control element. Science 1993;259:984–987.

    Article  PubMed  CAS  Google Scholar 

  77. Griffiths GM, Berek C, Kaartinen M, Milstein C. Somatic mutation and the maturation of immune response to 2-phenyloxazo-lone. Nature 1984;312:271–275.

    Article  PubMed  CAS  Google Scholar 

  78. Cambier JC, Pleiman CM, Clark MR. Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol 1994;12:457–486.

    Article  PubMed  CAS  Google Scholar 

  79. Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994;15:437–442.

    Article  PubMed  CAS  Google Scholar 

  80. Lederman S, Yellin MJ, Inghirami G, et al. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles: roles of the T cell-B cell activating molecule (5c8 antigen) and CD40 in contact dependent help. J Immunol 1992;149:3817–3826.

    PubMed  CAS  Google Scholar 

  81. Takeuchi Y, Porter CD, Strahan KM, et al. Sensitization of cells and retroviruses to human serum by (a1-3) galactosyl transferase. Nature 1996;379:85–88.

    Article  PubMed  CAS  Google Scholar 

  82. Arai KI, Lee F, Miyajima A, et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990;59:783–836.

    Article  PubMed  CAS  Google Scholar 

  83. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998;16:205–226.

    Article  PubMed  CAS  Google Scholar 

  84. Feldman M, Londei M, Haworth C. T cells and lymphokines. Br Med Bull 1989;45:361–370.

    Google Scholar 

  85. Leonard WJ, Depper JM, Robb RJ, et al. Characterization of the human receptor for T cell growth factor. Proc Natl Acad Sci USA 1983;8:6957–6961.

    Article  Google Scholar 

  86. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone, I: definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.

    PubMed  CAS  Google Scholar 

  87. Mosmann TR. Cytokines: is there biological meaning? Curr Opin Immunol 1991;3:311–314.

    Article  PubMed  CAS  Google Scholar 

  88. Sugamura K, Asao H, Kondo M, et al. The common gamma-chain for multiple cytokine receptors. Adv Immunol 1995;59:225–277.

    Article  PubMed  CAS  Google Scholar 

  89. Aaronson DS, Horvath CM. A road map for those who don’t know JAK-STAT. Science 2002;296:1653–1655.

    Article  PubMed  CAS  Google Scholar 

  90. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995;16:374–380.

    Article  PubMed  CAS  Google Scholar 

  91. Krams SM, Falco DA, Villaneuva JC, et al. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation 1992;53:151–156.

    Article  PubMed  CAS  Google Scholar 

  92. Kirk AD, Bollinger RR, Finn OJ. Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 1995;43:113–128.

    Article  PubMed  CAS  Google Scholar 

  93. Allison JP, Krummel MF. The yin and yang of T cell costimula-tion. Science 1995;270:932–933.

    Article  PubMed  CAS  Google Scholar 

  94. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:396–404.

    Article  PubMed  CAS  Google Scholar 

  95. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997;9:641–647.

    Article  PubMed  CAS  Google Scholar 

  96. Harlan DM, Kirk AD. Anti-CD 154 therapy to prevent graft rejection. Graft 1998;1:63–70.

    Google Scholar 

  97. Bennett SRM, Carbone FR, Karamalis F, et al. Help for cytotoxic T cell responses is mediated by CD40 signalling. Nature 1998;393:478–480.

    Article  PubMed  CAS  Google Scholar 

  98. Schoenberger SP, Toes REM, van der Voort EIH, et al. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480–483.

    Article  PubMed  CAS  Google Scholar 

  99. Henn V, Slupsky JR, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.

    Article  PubMed  CAS  Google Scholar 

  100. Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol 2004;32:135–139.

    Article  PubMed  CAS  Google Scholar 

  101. Blair PJ, Riley JL, Levine BL, et al. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction. J Immunol 1998;160:12–15.

    PubMed  CAS  Google Scholar 

  102. Waterhouse P, Penninger JM, Timms E, et al. Lymphoprolifera-tive disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985–988.

    Article  PubMed  CAS  Google Scholar 

  103. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405–413.

    Article  PubMed  CAS  Google Scholar 

  104. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793–801.

    Article  PubMed  CAS  Google Scholar 

  105. Pennisi E. Teetering on the brink of danger. Science 1996;271:1665–1667.

    Article  PubMed  CAS  Google Scholar 

  106. Bingaman AW, Ha J, et al. Vigorous allograft rejection in the absence of danger. J Immunol 2000;164:3065–3071.

    PubMed  CAS  Google Scholar 

  107. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 2002;14:779–82.

    Article  PubMed  CAS  Google Scholar 

  108. Campbell RD, Trowsdale J. Map of the major histocompatibility complex. Immunol Today 1993;14:349–352.

    Article  PubMed  CAS  Google Scholar 

  109. Lotteau V, Teyton L, Borroghs D, Charron D. A novel HLA class II molecule (DRalpha-DQbeta) created by mismatched isotype pairing. Nature 1987;329:339–341.

    Article  PubMed  CAS  Google Scholar 

  110. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 1996;272:67–74.

    Article  PubMed  CAS  Google Scholar 

  111. Nowak MA, Bangham CRM. Population dynamics of immune responses to persistent viruses. Science 1996;272:74–79.

    Article  PubMed  CAS  Google Scholar 

  112. Salter RD, Benjamin RJ, Wesley PK, et al. A binding site for the T cell co-receptor CD8 on the a3 domain of HLA-A2. Nature 1990;345:41–46.

    Article  PubMed  CAS  Google Scholar 

  113. Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1987;330:256–259.

    Article  PubMed  CAS  Google Scholar 

  114. Williams DB, Barber BH, Flavell RA, et al. Role of b2-microglo-bin in the intracellular transport and surface expression of murine class I histocompatibility molecules. J Immunol 1989;142:2796–2806.

    PubMed  CAS  Google Scholar 

  115. Teyton L, O’Sullivan D, Dickson PW, et al. Invariant chain distinguishes between the exogenous and endogenous antigen presenting pathways. Nature 1988;348:39–44.

    Article  Google Scholar 

  116. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003;196:147.

    Article  PubMed  CAS  Google Scholar 

  117. Halloran PF, Madrenas J. Regulation of MHC transcription. Transplantation 1990;50:725–738.

    Article  PubMed  CAS  Google Scholar 

  118. Gerritsen ME, Bloor CM. Endothelial cell gene expression in response to injury. FASEB 1993;7:523–533.

    CAS  Google Scholar 

  119. Marsh SGE, Bodmer JG. HLA class II nucleotide sequences, 1992. Immunogenetics 1993;37:79–94.

    Article  PubMed  CAS  Google Scholar 

  120. Zemmour J, Parham P. HLA class I nucleotide sequences, 1992. Immunogenetics 1993;37:239–250.

    Article  PubMed  CAS  Google Scholar 

  121. Bidwell J. DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens. Immunol Today 1998;9:18–23.

    Article  Google Scholar 

  122. Nevinny-Stickel C, Bettinotti MP, Andreas A, et al. Nonradioactive HLA class II typing using polymerase chain reaction and digoxigenin-11-29-39-didesoxy-uridinetriphosphate labeled oligonucleotide probes. Hum Immunol 1991;31:7–13.

    Article  PubMed  CAS  Google Scholar 

  123. Nevinny-Stickel C, Hinzpter M, Andreas A, et al. Nonradioactive oligotyping for HLA-DRl-DRwlO using polymerase chain reaction, digoxigenin-labeled oligonucleotides and chemilumi-nescence detection. Eur J Immunogenet 1991;18:323–332.

    Article  PubMed  CAS  Google Scholar 

  124. Olerup O, Zetterquist H. HLA DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens 1992;39:225–235.

    Article  PubMed  CAS  Google Scholar 

  125. Markus BH, Duquesnoy RJ, Gordon RD, et al. Histocompatibility and liver transplantation. Does HLA exert a dualistic effect? Transplantation (Baltimore) 1988;46:372–377.

    PubMed  CAS  Google Scholar 

  126. Steinhoff G. HLA/ABO matching. In Neuberger J, Adams D, eds. Immunology of Liver Transplantation. London: Edward Arnold; 1993:261–266.

    Google Scholar 

  127. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333–336.

    Article  PubMed  CAS  Google Scholar 

  128. Terasaki PI, Cecka JM, Gjertson DW, Cho YW. Spousal and Other Living Renal Donor Transplants. Los Angeles: UCLA Tissue Typing Laboratory, Clinical Transplants; 1997.

    Google Scholar 

  129. Gloor JM, DeGoey SR, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. AJT 3:1017, 2003:1017–1023.

    Google Scholar 

  130. Takahashi K, Saito K, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004;4:1089–1096.

    Article  PubMed  Google Scholar 

  131. Burdick JF. An anatomy of rejection. Transplant Rev 1991;5:81–90.

    Google Scholar 

  132. Kirk AD, Ibrahim MA, Bollinger RR, et al. Renal allograft infiltrating lymphocytes: a prospective analysis of in vitro growth characteristics and clinical relevance. Transplantation 1992;53:329–338.

    Article  PubMed  CAS  Google Scholar 

  133. Fuggle SV, Koo DDH. Cell adhesion molecules in clinical renal transplantation. Transplantation 1998;65:763–769.

    Article  PubMed  CAS  Google Scholar 

  134. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.

    Article  PubMed  CAS  Google Scholar 

  135. Takada M, Chandraker A, Nadeau KC, et al. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfu-sion injury. J Clin Invest 1997;100:1199–1203.

    Article  PubMed  CAS  Google Scholar 

  136. Dallman MJ, Clark GJ. Cytokines and their receptors in transplantation. Curr Opin Immunol 1991;3:729–734.

    Article  PubMed  CAS  Google Scholar 

  137. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 1997;94:695–700.

    Article  PubMed  CAS  Google Scholar 

  138. Levitz SM, Mathews HL, Murphy JW. Direct antimicrobial activity of T cells. Immunol Today 1995;16:387–391.

    Article  PubMed  CAS  Google Scholar 

  139. Baldwin WM III, Pruitt SK, Sanfilippo F, et al. Alloanti-bodies: basic and clinical concepts. Transplant Rev 1991;5:100–119.

    Google Scholar 

  140. Saadi S, Piatt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995;181:21–31.

    Article  PubMed  CAS  Google Scholar 

  141. Bach FH, Winkler H, Ferran C, et al. Delayed xenograft rejection. Immunol Today 1996;17:379–384.

    Article  PubMed  CAS  Google Scholar 

  142. Gebel HM, Lebeck LK. Crossmatch procedures used in organ transplantation. Clin Lab Med 1991;11:603–620.

    PubMed  CAS  Google Scholar 

  143. Talbot D. The flow cytometric crossmatch in perspective. Transplant Immunol 1993;1:155–162.

    Article  CAS  Google Scholar 

  144. Le Bas-Bernardet S, Hourmant M. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003;75:477–482.

    Article  PubMed  Google Scholar 

  145. Noreen HJ, McKinley DM, et al. Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003;75:501–505.

    Article  PubMed  Google Scholar 

  146. Colvin RB. The pathogenesis of vascular rejection. Transplant Proc 1991;23:2052–2055.

    PubMed  CAS  Google Scholar 

  147. Paul LC. Chronic renal transplant loss. Kidney Int 1995;47:1491–1499.

    Article  PubMed  CAS  Google Scholar 

  148. Almond PS, Matas A, Gillingham KJ, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752–757.

    Article  PubMed  CAS  Google Scholar 

  149. Gourishankar S, Halloran PF. Late deterioration of organ transplants: a problem in injury and homeostasis. Curr Opin Immunol 2002;14:576–583.

    Article  PubMed  CAS  Google Scholar 

  150. Ahsan N, Johnson C, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation. 2001;72:245–250.

    Article  PubMed  CAS  Google Scholar 

  151. Jensick SC. Tacrolimus in kidney transplantation: 3-year survival results of the US multicenter, randomized, comparative trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998;30:1216–1218.

    Article  Google Scholar 

  152. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at 3 years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65:1450–1454.

    Article  PubMed  CAS  Google Scholar 

  153. Gaber A. Results of the double-blind, randomized, multicenter, phase in clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Clin Transplant 1998;66:29–37.

    CAS  Google Scholar 

  154. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000;356:194–202.

    Article  PubMed  CAS  Google Scholar 

  155. Vincenti F. Interleukin-2-receptor blockade with daclizimab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161–165.

    Article  PubMed  CAS  Google Scholar 

  156. Hardinger KL, Schnitzler MA, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004;78:136–141.

    Article  PubMed  CAS  Google Scholar 

  157. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995;270:286–290.

    Article  PubMed  CAS  Google Scholar 

  158. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IkBoc in mediation of immunosuppression by glucocorticoids. Science 1995;283:283–286.

    Article  Google Scholar 

  159. Plaz KP, Sollinger HW, Hullet DA, et al. RS-61443, a new, potent immunosuppressive agent. Transplantation 1991;51:27–31.

    Google Scholar 

  160. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428–432.

    Article  PubMed  CAS  Google Scholar 

  161. Sollinger HW. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225–232.

    Article  PubMed  CAS  Google Scholar 

  162. Kahan BD. Role of cyclosporine: present and future. Transplant Proc 1994;26:3082–3087.

    PubMed  CAS  Google Scholar 

  163. Khanna A, Sharma VK, Suthanthiran M. Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-b expression. Transplant Proc 1996;28:2015–2019.

    PubMed  CAS  Google Scholar 

  164. Kirk AD, Jacobson LM, Heisey DM, et al. Post-transplant diastolic hypertension: associations with intragraft TGF-P, endo-thelin and renin transcription. Transplantation 1997;64:1716–1720.

    Article  PubMed  CAS  Google Scholar 

  165. June CH, Ledbetter JA, Gillespie MM, et al. T cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin-2 gene expression. Mol Cell Biol 1987;7:4472–4481.

    PubMed  CAS  Google Scholar 

  166. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530–534.

    Article  PubMed  CAS  Google Scholar 

  167. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256–1265.

    PubMed  CAS  Google Scholar 

  168. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686–3690.

    Article  PubMed  CAS  Google Scholar 

  169. Starzl TE, Fung JJ, Venkataramanan, et al. FK-506 for liver, kidney, and pancreas transplantation. Lancet 1989;334:1000–1004.

    Article  Google Scholar 

  170. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998;66:29–37.

    Article  PubMed  CAS  Google Scholar 

  171. Merion RM, Howell T, Bromberg JS. Partial T cell activation and energy induction by polyclonal antithymocyte globulin. Transplantation 1998;65:1481–1489.

    Article  PubMed  CAS  Google Scholar 

  172. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002;360:1662.

    Article  PubMed  CAS  Google Scholar 

  173. Starzl TE, Murase N, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502–1510.

    Article  PubMed  Google Scholar 

  174. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011–1018.

    Article  PubMed  CAS  Google Scholar 

  175. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996;51:865–894.

    Article  PubMed  CAS  Google Scholar 

  176. Delmonico FL, Cosimi AB. Monoclonal antibody treatment of human allograft recipients. Surg Obst Gynecol 1988;166:89–98.

    CAS  Google Scholar 

  177. Kupfer A, Mosmann TR, Kupfer H, et al. Polarized expression of cytokines in cell conjugates of helper T cells and splenic B cells. Proc Natl Acad Sci U S A 1991;88:775–779.

    Article  PubMed  CAS  Google Scholar 

  178. Shield CF III, Norman DJ. Immunological monitoring during and after OKT3 therapy. Am J Kidney Dis 1988;11:120–124.

    PubMed  Google Scholar 

  179. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985;313:337–342.

    Google Scholar 

  180. Light JA, Khawand N, Aquino A, et al. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin. Am J Kidney Dis 1989;14:10–13.

    PubMed  CAS  Google Scholar 

  181. Soulillou JP, Le Mauff B, Olive D, et al. Prevention of rejection of kidney transplants by a monoclonal antibody directed against interleukin 2. Lancet 1987;1:1339–1342.

    Article  PubMed  CAS  Google Scholar 

  182. Nashan B, Moore B, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;350:1193–1198.

    Article  PubMed  CAS  Google Scholar 

  183. Flechner M, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070–1076.

    Article  PubMed  CAS  Google Scholar 

  184. Segal SN, Baker H, Vezina C, et al. Rapamycin (AY-22,989), a new antifungal antibiotic, II: fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727–732.

    Google Scholar 

  185. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55:48–51.

    PubMed  CAS  Google Scholar 

  186. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic, III: In vitro and in vivo evaluation. J Antibiot 1978;31:539–545.

    PubMed  CAS  Google Scholar 

  187. Molnar-Kimber KL. Mechanism of action of rapamycin (sirolimus, rapamune). Transplant Proc 1996;26:964–969.

    Google Scholar 

  188. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990;144:1418–1424.

    PubMed  CAS  Google Scholar 

  189. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144:251–258.

    PubMed  CAS  Google Scholar 

  190. Kuo CJ, Chung J, Fiorentino DF, et al. Rapamycin selectively inhibits interleukin 2 activation of p70 S6 kinase. Nature 1992;358:70–73.

    Article  PubMed  CAS  Google Scholar 

  191. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60:264–270.

    Article  PubMed  CAS  Google Scholar 

  192. Bjorn Nashan. Review of the proliferation inhibitor everolimus. Exper Opin Invest Drug 2002;11:1845–1857.

    Article  Google Scholar 

  193. McAlister VC, Gao Z, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376–377.

    Article  PubMed  CAS  Google Scholar 

  194. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992;6:39–87.

    Google Scholar 

  195. Calne RY, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:1701.

    Article  PubMed  CAS  Google Scholar 

  196. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003;76:120.

    Article  PubMed  CAS  Google Scholar 

  197. Knechtle SJ, Pirsch JD, Fechner H, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722.

    Article  PubMed  CAS  Google Scholar 

  198. Kaufman DB. 15-Deoxyspergualin in experimental transplant models: a review. Transplant Proc 1996;28:868–870.

    PubMed  CAS  Google Scholar 

  199. Ramos EL, Nadler SG, Grasela DM, Kelly SL. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996;28:873–875.

    PubMed  CAS  Google Scholar 

  200. Kirk A. Results from a human tolerance trial using alemtuzumab (campath-lH) with deoxyspergualin (DSG). Am J Transplant 2003;3(S5):S310.

    Google Scholar 

  201. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019.

    Article  PubMed  CAS  Google Scholar 

  202. Becker YT, Becker BN, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996.

    Article  PubMed  CAS  Google Scholar 

  203. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484.

    Article  PubMed  CAS  Google Scholar 

  204. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001;98:3136–3142.

    Article  PubMed  CAS  Google Scholar 

  205. Takemoto SK, Zeevi A, et al. National Conference to Assess Antibody-Mediated Rejection in Solid Organ Transplantation. Am J Transplant 2004;4:1033–1041.

    Article  PubMed  CAS  Google Scholar 

  206. Kirk AD. Transplant tolerance: a look at the non-human primate literature in the view of modern tolerance theories. Crit Rev Immunol 1999;19:349–388.

    PubMed  CAS  Google Scholar 

  207. Kirk AD, Knechtle SJ, Sollinger H, Vincenti FG, Stecher S, Nadeau K. Preliminary results of the use of humanized anti-CD 154 in human renal allotransplantation. Am J Transplant 2001;1:S191.

    Google Scholar 

  208. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613–1616.

    Article  PubMed  CAS  Google Scholar 

  209. Kirk A. Results from a human tolerance trial using alemtuzumab (campath-IH) with deoxyspergualin (DSG). Am J Transplant 2003;3(S5):S310.

    Google Scholar 

  210. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480.

    Article  PubMed  CAS  Google Scholar 

  211. Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Clinical transplantation tolerance 12 years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 2000;69:1549.

    Article  PubMed  CAS  Google Scholar 

  212. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002;73:1386.

    Article  PubMed  Google Scholar 

  213. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789.

    Article  PubMed  CAS  Google Scholar 

  214. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD 154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686.

    Article  PubMed  CAS  Google Scholar 

  215. Elster EA, Xu H, Tadaki DK, et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 2001;72:1473.

    Article  PubMed  CAS  Google Scholar 

  216. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002;74:933.

    Article  PubMed  CAS  Google Scholar 

  217. Montgomery SP, Xu H, Tadaki DK, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD 154 in nonhuman primate renal transplantation. Transplantation 2002;74:1365.

    Article  PubMed  CAS  Google Scholar 

  218. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001;72:377–384.

    Article  PubMed  CAS  Google Scholar 

  219. Knechtle SJ, Fechner JH Jr, Dong Y, et al. Primate renal transplants using immunotoxin. Surgery 1998;124:438.

    PubMed  CAS  Google Scholar 

  220. Hutchings A, Wu J, Asiedu C, et al. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003;11:335.

    Article  PubMed  CAS  Google Scholar 

  221. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999;68:1767.

    Article  PubMed  CAS  Google Scholar 

  222. Kawai T, Abrahamian G, Sogawa H, et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc 2001;33:221.

    Article  PubMed  CAS  Google Scholar 

  223. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465–474.

    PubMed  CAS  Google Scholar 

  224. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997;63:1–6.

    Article  PubMed  CAS  Google Scholar 

  225. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplant tolerance. Immunol Today 1998;9:23–27.

    Article  Google Scholar 

  226. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989;169:493–502.

    Article  PubMed  CAS  Google Scholar 

  227. Kaufman CL, Ildstad ST. Induction of donor-specific tolerance by transplantation of bone marrow. Ther Immunol 1994;1:101–111.

    PubMed  CAS  Google Scholar 

  228. Odorico JS, O’Connor T, Campos L, et al. Examination of the mechanisms responsible for tolerance induction after intrathymic inoculation of allogeneic bone marrow. Ann Surg 1993;218:525–531.

    Article  PubMed  CAS  Google Scholar 

  229. Qin S, Cobbold SP, Pope H, et al. Infectious transplant tolerance. Science 1993;259:974–977.

    Article  PubMed  CAS  Google Scholar 

  230. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism and graft acceptance. Lancet 1992;339:1579–1582.

    Article  PubMed  CAS  Google Scholar 

  231. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434–438.

    Article  PubMed  CAS  Google Scholar 

  232. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789–8794.

    Article  PubMed  CAS  Google Scholar 

  233. Auchincloss H Jr, Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998;16:433–470.

    Article  PubMed  CAS  Google Scholar 

  234. Sandrin MS, Vaughan HA, et al. Anti-pig IgM antibodies in human serum react predominantly with gal(al-3)gal epitopes. Proc Natl Acad Sci U S A 1993;90:11391–11395.

    Article  PubMed  CAS  Google Scholar 

  235. Cooper DKC, Good AH, et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993;1:198–205.

    Article  PubMed  CAS  Google Scholar 

  236. Prilliman K, Lawlor D, Ellexson M. Characterization of baboon class I major histocompatibility molecules. Transplantation 1996;61:989–996.

    Article  PubMed  CAS  Google Scholar 

  237. Kirk AD, Li RA, Kinch MS, et al. The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. Transplantation 1993;55:924–931.

    Article  PubMed  CAS  Google Scholar 

  238. Tadaki D, Saini A, Craighead N, et al. Costimulatory pathways are active in xenogeneic immune responses [abstract]. Transplantation 1998;65:87.

    Article  Google Scholar 

  239. Reemtsma K, McCracken BH, et al. Renal heterotransplantation in man. Ann Surg 1964;160:384.

    Article  PubMed  CAS  Google Scholar 

  240. Starzl TE, Marchioro TL, et al. Renal heterotransplantation from baboon to man: experience with six cases. Transplantation 1964;2:752–759.

    Article  PubMed  CAS  Google Scholar 

  241. Bailey LL, Nehlsen-Cannarella SL, et al. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985;254:3321–3329.

    Article  PubMed  CAS  Google Scholar 

  242. Piatt JL, Fischel RJ, et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991;52:214–220.

    Article  Google Scholar 

  243. Goodman DJ, von Albertini M, et al. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996;61:763–771.

    Article  PubMed  CAS  Google Scholar 

  244. McCurry KR, Kooyman DL, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995;1:423–427.

    Article  PubMed  CAS  Google Scholar 

  245. Sandrin MS, Fodor WL, et al. Enzymatic remodeling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1996;1:1261–1267.

    Article  Google Scholar 

  246. Lai L, Kolber-Simonds D, et al. Production of α-1,3-galactosyl-transferase knockout pigs by nuclear transfer cloning. Science 2002:295:1089–1092.

    Article  PubMed  CAS  Google Scholar 

  247. Cozzi E, Bhatti FNK, Schmoeckel M, et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000;70:12–21.

    Google Scholar 

  248. Bhatti FNK, Schmoeckel M, Zaidi A, et al. Three-month survival of HDAFF transgenic pig hearts transplanted into primates. Transplant Proc 1999;31:958.

    Article  PubMed  CAS  Google Scholar 

  249. Vial CM, Ostlie DJ, Bhatti FNK, et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000;19:224–229.

    Article  PubMed  CAS  Google Scholar 

  250. Burke F, Naylor MS, et al. The cytokine wall chart. Immunol Today 1993;14:165.

    Article  PubMed  CAS  Google Scholar 

  251. Kirk AD, Sollinger HW. Transplant immunology and immunosuppression. In: Schwartz S, ed. Principles of Surgery, 7th Ed. New York; McGraw-Hill, 1998.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Transplantation Branch, National Institutes of Health, Bethesda, MD, USA

    Allan D. Kirk MD, PhD (Chief) & Eric A. Elster MD (Assistant Professor)

  2. Department of Surgery, Uniformed Services University, Bethesda, MD, USA

    Eric A. Elster MD (Assistant Professor)

Authors
  1. Allan D. Kirk MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric A. Elster MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  2. Divisions of Surgical Oncology and General Surgery, Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  3. Departments of Surgery and Public Health, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  4. Division of Critical Care and Trauma, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  5. Departments of Surgery and Immunology, Duke University Medical Center, Durham, NC, USA

    R. Randal Bollinger MD, PhD, FACS (Professor) (Professor)

  6. Division of Surgical Oncology, Department of Surgery, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA

    Alfred E. Chang MD, FACS (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  7. Department of Surgery, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  8. Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  9. Department of Surgery, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  10. Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  11. Departments of Cardiothoracic Surgery and Surgery, New York University Medical Center, New York, NY, USA

    Harvey I. Pass MD, FACS (Professor) (Professor)

  12. Radiology, and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

  13. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kirk, A.D., Elster, E.A. (2008). Immunology of Transplantation. In: Norton, J.A., et al. Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68113-9_81

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68113-9_81

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-30800-5

  • Online ISBN: 978-0-387-68113-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation